Bessemer Group’s Terns Pharmaceuticals TERN Stock Holding History

Bessemer Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29K	Hold	541	–	–	﹤0.01%	1830
2025 Q4	$22K	Buy	+541	New	+$12.5K	﹤0.01%	1860
2024 Q4	–	Sell	-185	Closed	-$2K	–	2686
2024 Q3	$2K	Buy	+185	New	+$1.52K	﹤0.01%	2279

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bessemer Group's TERN Position: Q1 2026 in Review

Bessemer Group held its Terns Pharmaceuticals (TERN) position steady in Q1 2026 at 541 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #1830.

Bessemer Group first reported a position in TERN in Q3 2024 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Bessemer Group held 541 shares of Terns Pharmaceuticals worth $29K as of Q1 2026.
Bessemer Group left its Terns Pharmaceuticals share count unchanged in Q1 2026.
Terns Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1830 holding.
Bessemer Group first reported a position in Terns Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.